Kilitch Drugs to Tap African Markets Aggressively with Ethiopian Plant

Kilitch Drugs Ltd, a fast growing pharmaceuticals company will now aggressively tap African markets with a state-of-the-art Cephalosporin injectable plant near Adis Ababa - capital city of Ethiopia. The unit will have a capacity of 20 million vials and commence operations in FY 2019 - 2020. Besides vials, the plant will also produce tablets, capsules, dry syrup, etc, top company officials said.

Mukund P Mehta, managing director, Kilitch Drugs Ltd, said that the company understands African markets well and believe that the region is the next bastion for growth. The company expects this project to become a shining example of India-Ethiopia partnership and bear testimony to increasing Indian investments in the region.

By 2020, Kilitch Drugs plans to register more than 500 products in the African markets. He said that Africa is a highly complex but profitable market. Our presence there would mean a potential doubling of revenues and significant improvement in margins.

Kilitch Drugs has joined hands with Estro to set up the manufacturing unit. Kilitch Drugs is the first company in Ethiopia to have a dedicated Cephalosporin injectable plant along with other oral dosage forms. Initially, the allocated land was 6700 sqm plot, later based on the progress and proposal submitted for expansion, Oromia Region Investment commission has allocated another 5700 sqm. of land, hence total land allocated is 12,400 sqm., said Mehta.

Kilitch has registered more than 275 products across Africa and is also setting up a new cephalosporin plant in Ethiopia.